A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis

2-year data

Michael R. McClung, Claude Laurent Benhamou, Zulema Man, Witold Tlustochowicz, Jose R. Zanchetta, Rachelle Eusebio, Ana M. Balske, Ellen Matzkin, Wojciech P. Olszynski, Robert R. Recker, Pierre D. Delmas

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

This 2-year trial evaluated the efficacy and tolerability of a monthly oral regimen of risedronate. Postmenopausal women with osteoporosis were randomly assigned to double-blind treatment with risedronate 75 mg on 2 consecutive days each month (2CDM) or 5 mg daily. The primary end point was the percentage change from baseline in lumbar spine bone mineral density (BMD) at 12 months. Secondary end points included the change in BMD of the lumbar spine and proximal femur and in bone turnover markers as well as the number of subjects with at least one new vertebral fracture over 24 months. Among 1,229 patients who were randomized and received at least one dose of risedronate, lumbar spine BMD was increased in both treatment groups: mean percentage change from baseline was 4.2 ± 0.19 and 4.3 ± 0.19 % in the 75 mg 2CDM and 5 mg daily groups, respectively, at month 24. The treatment difference was 0.17 (95 % confidence interval -0.35 to 0.68). There were no statistically significant differences between treatment groups on any secondary efficacy parameters. Both treatment regimens were well tolerated. Risedronate 75 mg 2CDM was noninferior in BMD efficacy and did not show a difference in tolerability compared to 5 mg daily after 24 months of treatment in women with postmenopausal osteoporosis. This monthly regimen may provide a more convenient dosing schedule to some patients with postmenopausal osteoporosis.

Original languageEnglish
Pages (from-to)59-67
Number of pages9
JournalCalcified Tissue International
Volume92
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Postmenopausal Osteoporosis
Bone Density
Spine
Therapeutics
Bone Remodeling
Femur
Osteoporosis
Risedronate Sodium
Appointments and Schedules
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

McClung, M. R., Benhamou, C. L., Man, Z., Tlustochowicz, W., Zanchetta, J. R., Eusebio, R., ... Delmas, P. D. (2013). A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data. Calcified Tissue International, 92(1), 59-67. https://doi.org/10.1007/s00223-012-9668-4

A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis : 2-year data. / McClung, Michael R.; Benhamou, Claude Laurent; Man, Zulema; Tlustochowicz, Witold; Zanchetta, Jose R.; Eusebio, Rachelle; Balske, Ana M.; Matzkin, Ellen; Olszynski, Wojciech P.; Recker, Robert R.; Delmas, Pierre D.

In: Calcified Tissue International, Vol. 92, No. 1, 01.2013, p. 59-67.

Research output: Contribution to journalArticle

McClung, MR, Benhamou, CL, Man, Z, Tlustochowicz, W, Zanchetta, JR, Eusebio, R, Balske, AM, Matzkin, E, Olszynski, WP, Recker, RR & Delmas, PD 2013, 'A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data', Calcified Tissue International, vol. 92, no. 1, pp. 59-67. https://doi.org/10.1007/s00223-012-9668-4
McClung, Michael R. ; Benhamou, Claude Laurent ; Man, Zulema ; Tlustochowicz, Witold ; Zanchetta, Jose R. ; Eusebio, Rachelle ; Balske, Ana M. ; Matzkin, Ellen ; Olszynski, Wojciech P. ; Recker, Robert R. ; Delmas, Pierre D. / A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis : 2-year data. In: Calcified Tissue International. 2013 ; Vol. 92, No. 1. pp. 59-67.
@article{d71cd577c8734ca1a877e4c2cf33cb5b,
title = "A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data",
abstract = "This 2-year trial evaluated the efficacy and tolerability of a monthly oral regimen of risedronate. Postmenopausal women with osteoporosis were randomly assigned to double-blind treatment with risedronate 75 mg on 2 consecutive days each month (2CDM) or 5 mg daily. The primary end point was the percentage change from baseline in lumbar spine bone mineral density (BMD) at 12 months. Secondary end points included the change in BMD of the lumbar spine and proximal femur and in bone turnover markers as well as the number of subjects with at least one new vertebral fracture over 24 months. Among 1,229 patients who were randomized and received at least one dose of risedronate, lumbar spine BMD was increased in both treatment groups: mean percentage change from baseline was 4.2 ± 0.19 and 4.3 ± 0.19 {\%} in the 75 mg 2CDM and 5 mg daily groups, respectively, at month 24. The treatment difference was 0.17 (95 {\%} confidence interval -0.35 to 0.68). There were no statistically significant differences between treatment groups on any secondary efficacy parameters. Both treatment regimens were well tolerated. Risedronate 75 mg 2CDM was noninferior in BMD efficacy and did not show a difference in tolerability compared to 5 mg daily after 24 months of treatment in women with postmenopausal osteoporosis. This monthly regimen may provide a more convenient dosing schedule to some patients with postmenopausal osteoporosis.",
author = "McClung, {Michael R.} and Benhamou, {Claude Laurent} and Zulema Man and Witold Tlustochowicz and Zanchetta, {Jose R.} and Rachelle Eusebio and Balske, {Ana M.} and Ellen Matzkin and Olszynski, {Wojciech P.} and Recker, {Robert R.} and Delmas, {Pierre D.}",
year = "2013",
month = "1",
doi = "10.1007/s00223-012-9668-4",
language = "English",
volume = "92",
pages = "59--67",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis

T2 - 2-year data

AU - McClung, Michael R.

AU - Benhamou, Claude Laurent

AU - Man, Zulema

AU - Tlustochowicz, Witold

AU - Zanchetta, Jose R.

AU - Eusebio, Rachelle

AU - Balske, Ana M.

AU - Matzkin, Ellen

AU - Olszynski, Wojciech P.

AU - Recker, Robert R.

AU - Delmas, Pierre D.

PY - 2013/1

Y1 - 2013/1

N2 - This 2-year trial evaluated the efficacy and tolerability of a monthly oral regimen of risedronate. Postmenopausal women with osteoporosis were randomly assigned to double-blind treatment with risedronate 75 mg on 2 consecutive days each month (2CDM) or 5 mg daily. The primary end point was the percentage change from baseline in lumbar spine bone mineral density (BMD) at 12 months. Secondary end points included the change in BMD of the lumbar spine and proximal femur and in bone turnover markers as well as the number of subjects with at least one new vertebral fracture over 24 months. Among 1,229 patients who were randomized and received at least one dose of risedronate, lumbar spine BMD was increased in both treatment groups: mean percentage change from baseline was 4.2 ± 0.19 and 4.3 ± 0.19 % in the 75 mg 2CDM and 5 mg daily groups, respectively, at month 24. The treatment difference was 0.17 (95 % confidence interval -0.35 to 0.68). There were no statistically significant differences between treatment groups on any secondary efficacy parameters. Both treatment regimens were well tolerated. Risedronate 75 mg 2CDM was noninferior in BMD efficacy and did not show a difference in tolerability compared to 5 mg daily after 24 months of treatment in women with postmenopausal osteoporosis. This monthly regimen may provide a more convenient dosing schedule to some patients with postmenopausal osteoporosis.

AB - This 2-year trial evaluated the efficacy and tolerability of a monthly oral regimen of risedronate. Postmenopausal women with osteoporosis were randomly assigned to double-blind treatment with risedronate 75 mg on 2 consecutive days each month (2CDM) or 5 mg daily. The primary end point was the percentage change from baseline in lumbar spine bone mineral density (BMD) at 12 months. Secondary end points included the change in BMD of the lumbar spine and proximal femur and in bone turnover markers as well as the number of subjects with at least one new vertebral fracture over 24 months. Among 1,229 patients who were randomized and received at least one dose of risedronate, lumbar spine BMD was increased in both treatment groups: mean percentage change from baseline was 4.2 ± 0.19 and 4.3 ± 0.19 % in the 75 mg 2CDM and 5 mg daily groups, respectively, at month 24. The treatment difference was 0.17 (95 % confidence interval -0.35 to 0.68). There were no statistically significant differences between treatment groups on any secondary efficacy parameters. Both treatment regimens were well tolerated. Risedronate 75 mg 2CDM was noninferior in BMD efficacy and did not show a difference in tolerability compared to 5 mg daily after 24 months of treatment in women with postmenopausal osteoporosis. This monthly regimen may provide a more convenient dosing schedule to some patients with postmenopausal osteoporosis.

UR - http://www.scopus.com/inward/record.url?scp=84871730958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871730958&partnerID=8YFLogxK

U2 - 10.1007/s00223-012-9668-4

DO - 10.1007/s00223-012-9668-4

M3 - Article

VL - 92

SP - 59

EP - 67

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - 1

ER -